Sponsor pipeline

Amicus Therapeutics clinical trial pipeline

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Phase 3

Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT06904261	A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and…	Fabry Disease	Recruiting	2026-09-01
NCT04808505	A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase…	Glycogen Storage Disease Type II Infantile Onset	Recruiting	2026-01-22
NCT03911505	ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in…	Pompe Disease (Late-onset)	Active, Not Recruiting	2026-09-17
NCT04020055	A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal…	Fabry Disease	Active, Not Recruiting	2026-07-06
Not specified
NCT06906367	A Study of Patients With Fabry Disease (US Specific)	Fabry Disease	Recruiting	2026-09-09
NCT06121011	A Global Prospective Observational Registry of Patients With Pompe Disease	Pompe Disease	Recruiting	2026-03-10
NCT04252066	A Global Prospective Observational Study of Women With Fabry Disease and Their Infants…	Fabry Disease	Recruiting	2025-07-08

Get alerts when Amicus Therapeutics's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.